128 related articles for article (PubMed ID: 11484974)
1. Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study.
Casali M; Marcellini M; Casali A; Giuntini T; Galante E; Ferrone C
J Exp Clin Cancer Res; 2001 Jun; 20(2):195-8. PubMed ID: 11484974
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Mertens WC; Eisenhauer EA; Moore M; Venner P; Stewart D; Muldal A; Wong D
Ann Oncol; 1993 Apr; 4(4):331-2. PubMed ID: 8518225
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Ryan CW; Vogelzang NJ; Stadler WM
Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor.
Slovin SF; Berg W; Olgac S; Reuter V; Scher H
Cancer Invest; 2004; 22(5):818-21. PubMed ID: 15581064
[No Abstract] [Full Text] [Related]
5. Gemcitabine: a phase II study in patients with advanced renal cancer.
De Mulder PH; Weissbach L; Jakse G; Osieka R; Blatter J
Cancer Chemother Pharmacol; 1996; 37(5):491-5. PubMed ID: 8599874
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Small EJ
Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
[TBL] [Abstract][Full Text] [Related]
8. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
Conter HJ; Lim ZD; Ng CS; Millikan RE; Tannir NM
Clin Genitourin Cancer; 2013 Sep; 11(3):370-3. PubMed ID: 23665133
[No Abstract] [Full Text] [Related]
9. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
Fujiwara Y; Kiura K; Tabata M; Takigawa N; Hotta K; Umemura S; Omori M; Gemba K; Ueoka H; Tanimoto M
Anticancer Drugs; 2008 Apr; 19(4):431-3. PubMed ID: 18454054
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
[TBL] [Abstract][Full Text] [Related]
11. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine.
Tippin DB; Reeves W; Vogelzang NJ
J Urol; 1999 Jul; 162(1):155-6. PubMed ID: 10379761
[No Abstract] [Full Text] [Related]
13. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
[TBL] [Abstract][Full Text] [Related]
14. Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma.
Lin CJ; Lim KH; Cheng YC; Chen HH; Wu CJ
Med Oncol; 2007; 24(4):455-7. PubMed ID: 17917099
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Moore MJ; Tannock IF; Ernst DS; Huan S; Murray N
J Clin Oncol; 1997 Dec; 15(12):3441-5. PubMed ID: 9396395
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
17. Erysipeloid skin toxicity induced by gemcitabine.
Zustovich F; Pavei P; Cartei G
J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):757-8. PubMed ID: 16836522
[No Abstract] [Full Text] [Related]
18. A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
George CM; Vogelzang NJ; Rini BI; Geoffroy FJ; Kollipara P; Stadler WM
Ann Oncol; 2002 Jan; 13(1):116-20. PubMed ID: 11863091
[TBL] [Abstract][Full Text] [Related]
19. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
20. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Oudard S; Banu E; Vieillefond A; Fournier L; Priou F; Medioni J; Banu A; Duclos B; Rolland F; Escudier B; Arakelyan N; Culine S;
J Urol; 2007 May; 177(5):1698-702. PubMed ID: 17437788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
